Patient-derived liver cancer organoids that preserve key genetic, histopathological, and therapeutic response characteristics of primary liver tumors, providing clinically relevant models for translational oncology, drug discovery, and precision medicine research.
- Overview
- Details
- Advantages
- FAQs
Overview
Liver cancer is one of the leading causes of cancer-related mortality worldwide, with hepatocellular carcinoma (HCC) accounting for the majority of primary liver cancer cases. The disease commonly develops in association with chronic liver injury, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and cirrhosis. Liver tumorigenesis is driven by diverse molecular alterations involving pathways such as Wnt/β-catenin, TP53, TERT, PI3K/AKT/mTOR, and MAPK signaling.
Liver cancer exhibits substantial heterogeneity across patients in terms of genetic background, histological features, disease progression, and therapeutic response. Conventional two-dimensional cell cultures often fail to preserve the complex architecture, cellular diversity, and patient-specific molecular characteristics of primary tumors, limiting their utility in translational research and drug development.
Our human liver cancer organoids are established from patient-derived tumor tissues and retain important histological, molecular, and functional characteristics of the original malignancies. These three-dimensional models provide a physiologically relevant platform for studying liver cancer biology, evaluating therapeutic efficacy, investigating resistance mechanisms, and supporting precision oncology applications.
What Pathological Features Do Liver Cancer Organoids Recapitulate?
- Histological architecture and cellular organization of primary liver tumors
- Common liver cancer-associated mutations involving TP53, CTNNB1, TERT, AXIN1, and ARID1A
- Aberrant Wnt/β-catenin, PI3K/AKT, and MAPK signaling pathway activation
- Expression of liver cancer biomarkers including AFP, GPC3, EpCAM, and CK19
- Cancer stem-like cell populations associated with tumor initiation and progression
- Patient-specific therapeutic sensitivity and resistance phenotypes
- Molecular and phenotypic heterogeneity observed across liver cancer subtypes
- Clinically relevant proliferation, invasion, and survival characteristics
These disease-relevant features make liver cancer organoids valuable tools for investigating hepatocarcinogenesis, identifying predictive biomarkers, and developing novel therapeutic strategies.
Fig. 1. Establishment of patient-derived liver cancer organoids (Dong R, Zhang B, et al., 2022).
Our Liver Cancer Organoids
Our liver cancer organoids are high-quality, ready-to-use human tumor models developed under optimized culture conditions to preserve clinically relevant disease characteristics while supporting reproducibility and scalability.
Disease-Relevant Features
- Patient-derived liver tumor models that preserve key phenotypic and molecular characteristics of primary cancers
- Tumor heterogeneity maintained through diverse cellular populations and differentiation states
- Representative genetic profiles reflecting common liver cancer-associated genomic alterations
- Disease-relevant biomarker expression suitable for translational and mechanistic studies
- Ready-to-use cryopreserved format enabling rapid experimental deployment
Characterization & Validation
Our liver cancer organoids undergo comprehensive characterization and validation to ensure biological relevance and experimental consistency.
- Genetic characterization: Analysis of clinically relevant mutations and liver cancer-associated molecular alterations
- Tumor biomarker expression: Validation of AFP, GPC3, EpCAM, CK19, and additional liver cancer markers
- 3D tumor morphology: Preservation of tissue architecture and tumor-specific structural characteristics
- Disease phenotype assessment: Evaluation of proliferation, pathway activation, and therapeutic response profiles
- Quality control: Post-thaw viability ≥85%, identity verification, low batch variability, and mycoplasma-free status
Applications
Our ready-to-use liver cancer organoids provide a versatile platform for a broad range of oncology research applications:
- Disease Mechanism Studies: Investigate hepatocarcinogenesis, tumor progression, and cancer stem cell biology.
- Drug Discovery & Screening: Evaluate small molecules, targeted therapies, biologics, and combination treatment strategies.
- Precision Oncology: Assess patient-specific therapeutic responses and biomarker-guided treatment approaches.
- Resistance Mechanism Research: Explore mechanisms underlying resistance to targeted therapies, kinase inhibitors, and immunotherapies.
- Target Validation: Identify and validate novel therapeutic targets using human-relevant liver cancer models.
Why Choose Our Liver Cancer Organoids
- More predictive than conventional 2D cancer models for evaluating therapeutic efficacy and resistance
- Disease-relevant organoids that preserve clinically important tumor phenotypes and molecular characteristics
- Ready-to-use, eliminating lengthy tumor model establishment procedures
- Reproducible, supported by rigorous quality control and batch consistency testing
- HTS-compatible, enabling scalable drug screening and therapeutic evaluation workflows
FAQs
Q: What disease phenotypes are validated in your liver cancer organoids?
Our organoids are validated for clinically relevant liver cancer characteristics including genetic alterations, biomarker expression, tumor morphology, pathway activation, and disease-specific therapeutic response profiles.
Q: Do the organoids retain tumor heterogeneity after cryopreservation?
Yes. Our optimized cryopreservation and recovery protocols are designed to maintain key cellular populations and disease-relevant phenotypes following thawing.
Q: What downstream assays can be performed using these organoids?
These organoids support a wide range of assays including viability testing, immunofluorescence staining, high-content imaging, qPCR, RNA sequencing, pathway analysis, genomic profiling, and drug response studies.
Q: Can customized liver cancer organoid models be generated?
Yes. We can support customized projects involving specific molecular backgrounds, patient-derived samples, and tailored disease modeling applications depending on research requirements.
Accelerate liver cancer research with physiologically relevant, ready-to-use human tumor organoids.
Contact us today to request detailed characterization data, pricing information, or customized liver cancer organoid solutions tailored to your research objectives.
Online Inquiry